Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010
Authors:
- Sharon K. GreeneSGSharon K. Greene
- Melisa RettMRMelisa Rett
- Eric S. WeintraubEWEric S. Weintraub
- Lingling LiLLLingling Li
- Ruihua YinRYRuihua Yin
- Anthony A. AmatoAAAnthony A. Amato
- Doreen T. HoDHDoreen T. Ho
- Sarah I. SheikhSSSarah I. Sheikh
- Bruce H. FiremanBFBruce H. Fireman
- Matthew F. DaleyMDMatthew F. Daley
- Edward A. BelongiaEBEdward A. Belongia
- Steven J. JacobsenSJSteven J. Jacobsen
Open Access
- 11 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 175 (11) , 1100-1109
Abstract
An increased risk of Guillain-Barré syndrome (GBS) following administration of the 1976 swine influenza vaccine led to a heightened focus on GBS when monovalent vaccines against a novel influenza A (H1N1) virus of swine origin were introduced in 2009. GBS cases following receipt of monovalent inactivated (MIV) and seasonal trivalent inactivated (TIV) influenza vaccines in the Vaccine Safety Datalink Project in 2009–2010 were identified in electronic data and confirmed by medical record review. Within 1–42 days following vaccination, 9 cases were confirmed in MIV recipients (1.48 million doses), and 8 cases were confirmed in TIV-only recipients who did not also receive MIV during 2009–2010 (1.72 million doses). Five cases following MIV and 1 case following TIV-only had an antecedent respiratory infection, a known GBS risk factor; furthermore, unlike TIV, MIV administration was concurrent with heightened influenza activity. In a self-controlled risk interval analysis comparing GBS onset within 1–42 days following MIV with GBS onset 43–127 days following MIV, the risk difference was 5.0 cases per million doses (95% confidence interval: 0.5, 9.5). No statistically significant increased GBS risk was found within 1–42 days following TIV-only vaccination versus 43–84 days following vaccination (risk difference = 1.1 cases per million doses, 95% confidence interval: −3.1, 5.4). Further evaluation to assess GBS risk following both vaccination and respiratory infection is warranted.Keywords
This publication has 36 references indexed in Scilit:
- H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink ProjectAmerican Journal of Preventive Medicine, 2011
- Guillain-Barre Syndrome, Influenzalike Illnesses, and Influenza Vaccination During Seasons With and Without Circulating A/H1N1 VirusesAmerican Journal of Epidemiology, 2011
- Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance OrganizationThe Pediatric Infectious Disease Journal, 2010
- Accuracy of influenza vaccination status in a computer-based immunization tracking system of a managed care organizationVaccine, 2010
- Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety Datalink ProjectAmerican Journal of Epidemiology, 2009
- Accuracy of Data on Influenza Vaccination Status at Four Vaccine Safety Datalink SitesAmerican Journal of Preventive Medicine, 2009
- Influenza Vaccination and Mortality: Differentiating Vaccine Effects From BiasAmerican Journal of Epidemiology, 2009
- Vaccines and Guillain-Barré SyndromeDrug Safety, 2009
- Tutorial in biostatistics: the self‐controlled case series methodStatistics in Medicine, 2005
- The Distribution of the Size of the Maximum Cluster of Points on a LineJournal of the American Statistical Association, 1965